Skip to main content
NVDA+1.05%AAPL0.00%GOOGL+0.86%MSFT+0.85%AMZN+0.83%TSM+2.75%SPCX+7.63%META+0.30%AVGO+2.08%TSLA+0.98%SKHY-0.06%MU+0.67%BRK-B+0.32%LLY+0.02%AMD-0.34%JPM0.00%WMT+0.78%ASMLa+0.43%V+2.51%XOM+0.01%JNJ-1.21%INTC-2.63%0700.HK+1.23%MA+2.23%ABBV+1.12%1398.HK+1.61%CSCO+0.55%LRCX-0.49%AP2d+1.25%AMAT+0.41%CVX-0.11%ORCL+0.18%COST+0.31%CAT+0.32%BAC+0.47%KO+1.00%DELL-1.86%PG+0.71%UNH+1.80%0005.HK+1.93%HSBA.L+0.95%3988.HK+1.69%ARM-1.49%1816.HK+0.48%GE-1.04%0857.HK+1.04%MS-0.06%0939.HK+1.47%PM+1.10%1288.HK+0.92%PLNJPY+0.91%USDZAR-0.85%USDPLN-0.82%USDMXN-0.69%AUDCHF+0.69%USDSEK-0.59%AUDJPY+0.58%CHFSEK-0.57%GBPCHF+0.48%GBPZAR-0.45%EURHKD+0.44%EURZAR-0.42%USDDKK-0.42%GBPTRY+0.41%AUDCAD+0.40%NOKJPY+0.40%GBPJPY+0.40%EURPLN-0.39%AUDUSD+0.39%NZDMXN-0.39%EURCNH+0.37%EURCHF+0.35%AUDNZD+0.34%GBPHKD+0.32%USDNOK-0.31%GBPCAD+0.29%GBPMXN-0.28%CHFNOK-0.28%NZDCHF+0.27%EURSGD+0.27%GBPUSD+0.26%AUDDKK-0.26%EURJPY+0.26%SGDJPY+0.25%EURAUD-0.24%GBPSGD+0.24%USDCHF+0.23%GBPNZD+0.22%EURCZK-0.21%CADCHF+0.20%NZDJPY+0.19%EURSEK-0.17%USDILS+0.16%USDSGD-0.16%GBPAUD-0.16%EURCAD+0.16%AUDNOK-0.16%USDJPY+0.15%NZDSGD+0.15%EURUSD+0.14%CHFSGD-0.14%EURNOK+0.12%EURGBP-0.12%CADJPY+0.11%EURNZD+0.11%USDTRY+0.10%USDTHB+0.09%CHFJPY-0.09%NZDCAD+0.07%USDCNH-0.06%USDCOP-0.04%NZDUSD+0.04%USDCAD+0.03%EURDKK+0.01%USDHKD+0.01%AUDSGD-0.01%UKOIL-2.53%USOIL-2.08%W1+0.98%C1+0.90%COFFEE+0.86%GAUUSD+0.85%XAUUSD+0.85%COCOA-0.82%GAGUSD+0.77%XAGUSD+0.76%S1+0.60%COTTON+0.59%BTCUSD+0.57%ETHUSD+6.15%USDTUSD-0.03%XRPUSD-0.54%SOLUSD-2.00%TRXUSDT-0.21%ZECUSDT+2.37%DOGEUSD-1.82%XMRUSDT-0.69%LINKUSD+3.21%XLMUSD+0.36%BCHUSDT+0.32%UNIUSD-1.99%LTCUSD-4.60%SUIUSD-0.91%HBARUSDT-0.12%TONUSD+12.52%TAOUSDT-0.70%AAVEUSD-0.90%DOTUSDT+0.28%ICPUSDT-3.98%ONDOUSDT-0.08%WLDUSDT+1.00%ARBUSDT-3.23%JUPUSDT-0.14%ATOMUSDT-0.58%INJUSDT+1.01%STXUSDT+0.08%FETUSDT-2.21%SEIUSDT-0.61%PYTHUSDT+1.08%TIAUSDT-1.21%IMXUSDT-1.75%GRTUSDT-0.52%OPUSDT-2.99%WIFUSDT+0.80%IOTAUSDT+3.96%AXSUSDT-0.86%POLUSDT+1.63%FARTCOINUSDT+2.17%EOSUSDT+3.59%DYDXUSDT-1.83%GALAUSDT-0.52%ORDIUSDT+1.37%NOTUSDT+1.29%RONINUSDT+4.44%NVDA+1.05%AAPL0.00%GOOGL+0.86%MSFT+0.85%AMZN+0.83%TSM+2.75%SPCX+7.63%META+0.30%AVGO+2.08%TSLA+0.98%SKHY-0.06%MU+0.67%BRK-B+0.32%LLY+0.02%AMD-0.34%JPM0.00%WMT+0.78%ASMLa+0.43%V+2.51%XOM+0.01%JNJ-1.21%INTC-2.63%0700.HK+1.23%MA+2.23%ABBV+1.12%1398.HK+1.61%CSCO+0.55%LRCX-0.49%AP2d+1.25%AMAT+0.41%CVX-0.11%ORCL+0.18%COST+0.31%CAT+0.32%BAC+0.47%KO+1.00%DELL-1.86%PG+0.71%UNH+1.80%0005.HK+1.93%HSBA.L+0.95%3988.HK+1.69%ARM-1.49%1816.HK+0.48%GE-1.04%0857.HK+1.04%MS-0.06%0939.HK+1.47%PM+1.10%1288.HK+0.92%PLNJPY+0.91%USDZAR-0.85%USDPLN-0.82%USDMXN-0.69%AUDCHF+0.69%USDSEK-0.59%AUDJPY+0.58%CHFSEK-0.57%GBPCHF+0.48%GBPZAR-0.45%EURHKD+0.44%EURZAR-0.42%USDDKK-0.42%GBPTRY+0.41%AUDCAD+0.40%NOKJPY+0.40%GBPJPY+0.40%EURPLN-0.39%AUDUSD+0.39%NZDMXN-0.39%EURCNH+0.37%EURCHF+0.35%AUDNZD+0.34%GBPHKD+0.32%USDNOK-0.31%GBPCAD+0.29%GBPMXN-0.28%CHFNOK-0.28%NZDCHF+0.27%EURSGD+0.27%GBPUSD+0.26%AUDDKK-0.26%EURJPY+0.26%SGDJPY+0.25%EURAUD-0.24%GBPSGD+0.24%USDCHF+0.23%GBPNZD+0.22%EURCZK-0.21%CADCHF+0.20%NZDJPY+0.19%EURSEK-0.17%USDILS+0.16%USDSGD-0.16%GBPAUD-0.16%EURCAD+0.16%AUDNOK-0.16%USDJPY+0.15%NZDSGD+0.15%EURUSD+0.14%CHFSGD-0.14%EURNOK+0.12%EURGBP-0.12%CADJPY+0.11%EURNZD+0.11%USDTRY+0.10%USDTHB+0.09%CHFJPY-0.09%NZDCAD+0.07%USDCNH-0.06%USDCOP-0.04%NZDUSD+0.04%USDCAD+0.03%EURDKK+0.01%USDHKD+0.01%AUDSGD-0.01%UKOIL-2.53%USOIL-2.08%W1+0.98%C1+0.90%COFFEE+0.86%GAUUSD+0.85%XAUUSD+0.85%COCOA-0.82%GAGUSD+0.77%XAGUSD+0.76%S1+0.60%COTTON+0.59%BTCUSD+0.57%ETHUSD+6.15%USDTUSD-0.03%XRPUSD-0.54%SOLUSD-2.00%TRXUSDT-0.21%ZECUSDT+2.37%DOGEUSD-1.82%XMRUSDT-0.69%LINKUSD+3.21%XLMUSD+0.36%BCHUSDT+0.32%UNIUSD-1.99%LTCUSD-4.60%SUIUSD-0.91%HBARUSDT-0.12%TONUSD+12.52%TAOUSDT-0.70%AAVEUSD-0.90%DOTUSDT+0.28%ICPUSDT-3.98%ONDOUSDT-0.08%WLDUSDT+1.00%ARBUSDT-3.23%JUPUSDT-0.14%ATOMUSDT-0.58%INJUSDT+1.01%STXUSDT+0.08%FETUSDT-2.21%SEIUSDT-0.61%PYTHUSDT+1.08%TIAUSDT-1.21%IMXUSDT-1.75%GRTUSDT-0.52%OPUSDT-2.99%WIFUSDT+0.80%IOTAUSDT+3.96%AXSUSDT-0.86%POLUSDT+1.63%FARTCOINUSDT+2.17%EOSUSDT+3.59%DYDXUSDT-1.83%GALAUSDT-0.52%ORDIUSDT+1.37%NOTUSDT+1.29%RONINUSDT+4.44%
EL

Edwards Lifesciences Corporation (EW)

NYSE • Healthcare

$87.23
+$2.07 (+2.4%)
Market closed

Last close at October 5, 2026 at 20:00 UTC

Open$85.64
Day Range$85.34 - $87.57
Avg. Volume (3M)3.5M
Market Cap$50.2B
P/E Ratio50.1
52 Week Range
$72.3$96.29
Next EarningsIn 23 daysOct 29, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$1.7B100%
Gross Profitminus cost of goods$1.3B78%
Operating Incomeminus R&D and overhead$519.5M30%
Net Incomeminus taxes and the rest$241.9M14%

In plain terms: out of every $100 in revenue, Edwards Lifesciences Corporation keeps $14 as net profit.

Fundamentals & Financials

Revenue (TTM)
$6.5B
Net Income (TTM)
$1B
EPS (TTM)
$1.74
ROA (TTM)
7.25%
Current Ratio
4.52

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-6.1%Q1 2026$0.58
+7.0%Q2 2026$0.78
+5.0%Q3 2026$0.78
Next

Oct 29

in 23 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +5.0%

Edwards Lifesciences’ revenue rose about 17% to roughly $1.7 billion in the first fiscal quarter of 2026, based on preliminary results, while net income increased about 6% to around $381 million. Operating income reached about $515 million, with gross margin near 78% and operating margin around 31%, showing profitability kept pace as the top line expanded. The company generated operating cash flow of about $43.8 million and repurchased roughly $522 million of stock.

Next report — what to expect

Edwards Lifesciences Corporation (EW) is set to report earnings on October 29, 2026. Wall Street consensus calls for EPS of $0.738 on revenue of $1.68 billion. For trailing context, revenue grew +13.6% year over year last quarter. Edwards has beaten EPS in 7 of 8 most recent quarters.

View full earnings history

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation (NYSE: EW) develops medical technology for structural heart disease, critical care, and surgical patient monitoring. The company sells to healthcare providers across the United States, Europe, Japan, and other international markets, and generated $6.1 billion of revenue in FY2025.

Name
Edwards Lifesciences Corporation
CEO
Bernard J. Zovighian
Website
www.edwards.com
Industry
Healthcare
Year Founded
1958
Employees
16,000

Today's Snapshot

AI-generated

EW closed 2.5% above yesterday's close, in line with a firmer sector. Trading was lighter than usual, with volume about two-thirds of its usual level. Edwards won FDA approval for Autus, an expandable pediatric heart valve.

Trading Volume

Below 10d avg (3.4M)

2.2M

vs S&P 500 Today

Outperforming Market

+1.72%

Updated: October 5, 2026 at 20:08 UTC

Technical Indicators

3 Buy2 Neutral3 Sell
EW displays a mixed profile that leans bearish: short-term averages sit slightly above the price while the 50/100-day moving averages remain resistance, and the 200-day average is below price, creating a patchwork of support and resistance that favors caution. Momentum and MACD show mild selling pressure and RSI is neutral, while ADX is low, indicating the market lacks a strong trend. Volume-based OBV and pivot levels are constructive, but they have not overcome soft momentum. Technical takeaway: Sell — weak trend and modest negative momentum amid mixed moving-average signals.
All signals
  • EMA (5 indicators)$85.38 - $87.86
    Buy
  • RSI (14)49.04
    Neutral
  • Stochastic %K (14, 3, 3)26.45
    Neutral
  • MACD Level (12, 26)-0.71
    Sell

Peers & Related Assets

CAHCardinal Health, Inc.
$233.12+2.1%
BDXBecton, Dickinson and Company
$180.67+2.2%
AAgilent Technologies, Inc.
$171.27+2.1%
VEEVVeeva Systems Inc.
$283.45+3.7%
DXCMDexCom, Inc.
$86.9+1.8%
STESTERIS plc
$211.07+1.2%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.